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Introduction: In cognitively normal (CN) adults, increased rates of amyloid beta (Aβ)
accumulation can be detected in low Aβ (Aβ–) apolipoprotein E (APOE) ε4 carriers. We
aimed to determine the effect of ε4 on the ability to benefit from experience (ie, learn)
in Aβ– CNs.
Methods: Aβ– CNs (n = 333) underwent episodic memory assessments every 18
months for 108months. A subset (n= 48) completed the Online Repeatable Cognitive
Assessment-Language Learning Test (ORCA-LLT) over 6 days.
Results: Aβ– ε4 carriers showed significantly lower rates of improvement on episodic
memory over 108 months compared to non-carriers (d = 0.3). Rates of learning on
the ORCA-LLT were significantly slower in Aβ– ε4 carriers compared to non-carriers
(d= 1.2).
Discussion: In Aβ– CNs, ε4 is associated with a reduced ability to benefit from expe-
rience. This manifested as reduced practice effects (small to moderate in magnitude)
over 108 months on the episodic memory composite, and a learning deficit (large in
magnitude) over 6 days on the ORCA-LLT. Alzheimer’s disease (AD)–related cognitive
abnormalities canmanifest before preclinical AD thresholds.
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1 INTRODUCTION
In cognitively normal (CN) older adults, elevated amyloid beta (Aβ+)
is associated with episodic memory dysfunction, hippocampal volume
loss, accumulation of Aβ, and increased rate of progression tomild cog-
nitive impairment (MCI) or dementia, relative to matched adults with
low Aβ (Aβ–).1,2 The severity of these clinical and biological manifes-
tations of Aβ+ is increased further by the apolipoprotein E (APOE)
ε4 allele3,4 proposed to be a consequence of ε4 disrupting normal Aβ
clearance.5 Subtle but increased rates of Aβ accumulation over 3 to
4 years can also be detected in ε4 carriers who remain Aβ–,6 raising
the possibility that cognitive changesmaybedetectable inAβ– ε4 carri-
ers if the study design or cognitive assessments applied have sufficient
sensitivity.
In the Australian Imaging, Biomarkers and Lifestyle (AIBL) study,
CNs completed seven neuropsychological assessments over 108
months providing greater power than previous investigations of Aβ–
groups to understand the effects of ε4 on cognition.3,7 However,
prospective investigations of cognitive change in AIBL, and in simi-
lar longitudinal cohorts, now show that in Aβ+ CNs, episodic memory
remains stable over5 to6years,whereas inmatchedAβ–CNs,memory
improves substantially over the same interval (ie, a practice effect).8–11
Reduced practice effects are proposed to be a strong clinical marker of
earlyAlzheimer’s disease (AD) pathologic changes in preclinical AD,9,11
and are therefore likely to occur in CN Aβ– ε4 carriers. However, we
have argued that a more parsimonious conceptualization of observa-
tions of reduced practice effects is that in very early AD, deficits in the
ability to benefit from experience (ie, to learn) are greater than deficits
in memory retrieval; at least as when measured by standardized tests
of episodic memory.10,12 We challenged this hypothesis in preclinical
AD, and found that deficits on a formal learning paradigm, evident over
6 days, were four times greater than the abnormal change in episodic
memory detected across the prior 6 years.12 Application of this learn-
ing model may therefore also inform understanding of any AD-related
cognitive dysfunction in CNAβ– ε4 carriers.
2 METHODS
2.1 Participants
Aβ– CN older adults (n = 333) enrolled in the AIBL study provided a
blood sample for APOE genotyping, and underwent serial neuropsy-
chological assessments every 18 months, for at least three timepoints.
A subgroup of these participants (n = 48), naïve to Chinese, Japanese
or Korean languages, also participated in a 6-day learning challenge
(Figure 1 summarizes the number of participants contacted, eligible,
enrolled, and included in this analysis). No participant had progressed
to MCI/AD. Recruitment and inclusion/exclusion criteria of AIBL have
been described previously.13,14 A clinical panel comprised of geria-
tricians, neurologists, and neuropsychologists determined the cogni-
tive normality of participants by examining all available medical and
RESEARCH INCONTEXT
Systematic Review: The authors reviewed the litera-
ture using traditional (eg, PubMed) sources, meet-
ing abstracts, and presentations. Studies reporting
on the role of apolipoprotein E (APOE) in low amy-
loid beta (Aβ)– cognitively normal older adults were
included. Studies on practice effects in the context
of aging and Alzheimer’s disease (AD) were also
reviewed.
Interpretation: Our findings are novel in showing that
reduced ability to benefit from experience (ie, learn)
is evident in Aβ– ε4 carriers. This manifested as
reduced practice effects over 108 months on the
episodic memory composite, albeit of a small-to-
moderate magnitude, and a learning deficit that
was large in magnitude over 6 days on the Online
Repeatable Cognitive Assessment-Language Learn-
ing Test (ORCA-LLT).
FutureDirections: Future studies are required todeter-
mine the extent to which other neuroinflammatory,
cerebrovascular, or neurodegenerative processes
may be related to this learning deficit in Aβ– adults.
Contacted n=184
No access to computer = 8
Terminal cancer = 1





Not interested = 64
Enrolled = 105
Withdrew = 8
Too burdensome = 4
Not interested = 3
No longer has access to computer = 1
F IGURE 1 Flowchart of the number of participants contacted,
enrolled, and completedOnline Repeatable Cognitive
Assessment-Language Learning Test (ORCA-LLT)
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TABLE 1 Demographic, clinical, cardiovascular, and neuroimaging characteristics









Mean (SD) Mean (SD) p Mean (SD) Mean (SD) p
N, Female (%) 154 (46.2) 33 (55.0) .842 18 (60.0) 5 (41.7) .281
Age at first assessment, y 69.37 (5.87) 67.69 (5.51) .044 74.40 (4.93) 73.85 (5.24) .735
Years of education 12.36 (2.96) 12.48 (3.05) .790 13.85 (2.87) 12.15 (3.11) .083
HADS-anxiety† 4.42 (2.85) 4.79 (3.58) .472 3.65 (2.97) 4.00 (3.70) .735
HADS-depression† 2.60 (2.25) 3.11 (2.44) .211 2.32 (2.23) 3.08 (2.66) .331
MMSE† 28.86 (1.20) 28.94 (1.10) .616 29.12 (1.04) 29.15 (1.21) .919
CDR Sum of Boxes† 0.03 (0.16) 0.04 (0.14) .736 0.04 (0.19) 0.19 (0.43) .108
Bodymass index 26.87 (4.15) 26.25 (3.61) .305 26.45 (3.67) 25.39 (3.17) .433
Abdominal circumference, cm 92.98 (13.28) 92.44 (13.19) .790 89.66 (11.27) 90.70 (7.62) .795
Diastolic blood pressure, mmHg 79.15 (10.33) 77.24 (8.73) .192 81.48 (9.18) 78.60 (7.72) .394
Systolic blood pressure, mmHg 136.52 (15.34) 139.19 (15.22) .230 136.74 (15.99) 136.80 (7.76) .991
Centiloid† 1.71 (9.87) 2.70 (9.69) .481 0.92 (4.63) -0.60 (10.13) .478
Hippocampal volume, cm3† 2.95 (0.29) 2.97 (0.25) .686 2.94 (0.25) 3.01 (0.28) .426
N years between first PET scan and baseline
AIBL cognitive assessment
3.28 (2.54) 2.61 (2.39) .064 – – –
N years betweenmost recent PET scan and
ORCA assessment
– – – 1.31 (1.22) 0.94 (0.84) .319
NAIBL cognitive assessments 6.14 (1.20) 6.27 (1.12) .464 5.21 (2.31) 4.69 (2.18) .492
Abbreviations: AIBL, Australian Imaging, Biomarkers and Lifestyle Study; CDR, Clinical Dementia Rating; CN, cognitively normal; HADS, Hospital Anxiety
and Depression Scale; MMSE, Mini-Mental State Examination; ORCA, Online Repeatable Cognitive Assessment; PET, positron emission tomography; SD,
standard deviation.
† obtained from the PET scan for the AIBL CN sample and closest PET scan to ORCA-LLT assessment for the ORCA subsample; bolded values are significant
at P< .05.
neuropsychological information. This clinical panelwas blind to genetic
and neuroimaging information. Participants were classified as cogni-
tively normal if they performed greater than –1 standard deviation on
all neuropsychological tests when compared to Australian norms, had
a Mini-Mental State Examination (MMSE) score of 26 or greater, and
a Clinical Dementia Rating (CDR) sum of boxes score of 0 or 0.5 (CDR
sumof boxes score of 0.5was acceptable if all neuropsychological tests
were within normative ranges). Demographic characteristics are sum-
marized in Table 1.
The AIBL study was approved by institutional research and ethics
committees.14 Human research ethics approval to conduct this study
was obtained throughMelbourneHealth.15 Informed consentwas pro-
vided in writing prior to participation in this study.
2.2 Episodic memory composite
The rationale and validation of the AIBL episodic memory com-
posite has been described.3 Raw scores on the California Verbal
Learning Test, Second Edition (CVLT-II) delayed recall trial, the Logical
Memory delayed recall trial, and the Rey Complex Figure Test (RCFT)
30-minute delayed recall trial were standardized using the baseline
mean and standard deviation of the Aβ– CN group, and averaged. As
has been reported previously, identical forms of these memory tests
were used at each assessment timepoint (administered in 18-month
intervals).16,17
2.3 Learning test
The Online Repeatable Cognitive Assessment-Language Learning Test
(ORCA-LLT) has also been described.12,15 This test measured the abil-
ity to learn the English language equivalent of 50 Chinese characters
over six sessions. Participants were required to determine whether
the English word and Chinese character had the same meaning. Ses-
sions consisted of two blocks of 200 trials of both correct and incor-
rect pairs with each block requiring approximately 10 minutes to
complete. Within each block, each Chinese character was presented
four times in random order. For two of these presentations, the Chi-
nese character was paired with the correct spoken English word.
For the remaining two presentations, incorrect spoken English words
were selected at random from the other possible 49 words. Each
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day of the task provided unique sets of incorrect pairings, while the
correct pairings stayed constant over time, to prevent off-target learn-
ing of incorrect pairs. Thus, the ratio of correct to incorrect pairings for
the first day was 4:2, for the second day was 8:2, for the third day was
12:2, for the fourth day was 16:2, for the fifth day was 20:2, and for
the final daywas 24:2. The order of trials was randomized for each ses-
sion and participant. Participantswere unaware of the underlying ratio
of correct to incorrect pairings, and no feedback regarding accuracy of
the decision was provided to participants. The primary outcome of the
ORCA-LLTwas accuracy (percentage of correct responses).
2.4 Neuroimaging
Aβ imaging with positron emission tomography (PET) was conducted
using one of four radioligands: Pittsburgh Compound B, florbetapir,
flutemetamol, or navidea. The acquisition protocol for each radioligand
has been detailed previously.13,18 Threshold values for elevated Aβ
deposition variedby radiotracer, so all standardizeduptakevalue ratios
(SUVR) were transformed onto the Centiloid scale using CapAIBL.19,20
Aβ– was classified if Centiloid scores were <15 at the closest imag-
ing visit relative to participants’ AIBL baseline cognitive assessment or
ORCA assessment.
2.4.1 Procedure
Participants completed the AIBL neuropsychological battery every 18
months. A subgroup completed the ORCA-LLT in their own homes
through aweb-based application using either a laptop or desktop com-
puter daily for 6 days. Assessors of the AIBL neuropsychological bat-
tery and the ORCA-LLT were blind to Aβ neuroimaging and genetic
results.
2.5 Data analysis
Analyses were conducted using R v.3.5.0. Although data distributions
for raw proportion correct performance scores on theORCA-LLTwere
distributed normally (Shapiro-Wilks test, Ps> .100 for all days), an arc-
sine square-root transformation was applied prior to analyses. Arc-
sine square-root transformations are used commonly for analyses of
proportion correct scores as they increase the range of possible val-
ues when scales are bounded by chance (ie, 50%) and a perfect score
(ie, 100%), which in turn can increase statistical power.21 To ensure
that this normalization did not distort outcomes, we repeated analyses
using raw proportion correct data to determine the similarity of con-
clusions drawn from analyses using transformed data.
Differences between APOE ε4 carriers and non-carriers in the rate
of change on the episodic memory composite were determined using a
linearmixed-effectsmodel (unstructured covariancematrix, maximum
likelihood estimation, participant as random factor). Similarly, the dif-
ference between ε4 carriers and non-carriers on the rate of learning on
the ORCA-LLT was determined using a linear mixed-effects model. For
theORCA-LLT, theAkaike information criterion (AIC) for the linear and
quadraticmodelswere1534.18 and1554.17, respectively,with the lin-
ear model demonstrating a significantly better fit (lower AIC values),
χ2 = 52.99, P< .001. Similarly, for the episodic memory composite, the
AIC for the linear and quadratic models were 4023.22 and 4042.91,
with the quadraticmodel not significantly better than the linearmodel,
χ2 = 1.53, P = .465. Age was included as a covariate in all models. The
unit of time for both mixed-effects models was test session (ie, months
for the episodicmemory composite and days forORCA-LLT). Cohen’s d
was used to express themagnitude of between-group differences.
3 RESULTS
3.1 Sample characteristics
APOE ε4 carriers were slightly younger than ε4 non-carriers, but were
equivalent on other demographic, clinical, cardiovascular, and neu-
roimaging characteristics (Table1). In theORCAsub-sample, ε4carriers
and non-carriers were matched on all demographic, clinical and neu-
roimaging characteristics. The average completion rate for the ORCA-
LLT was 98% across all days, with the lowest completion rate observed
onDay 6 (ie, 96%).
3.2 Effect of APOE ε4 on episodic memory
and short-term learning
For the episodic memory composite, a significant ε4 x time interaction
was observed. Decomposition of the interaction indicated that Aβ–CN
ε4 carriers demonstrated a significantly slower rate of improvement
over 108months compared toAβ–CN ε4 non-carriers (Figure 2A). This
difference was small to moderate in magnitude (Table 2). Analyses of
the ORCA-LLT learning curves indicated that ε4 carriers showed sig-
nificantly slower rates of learning compared to ε4 non-carriers (mod-
eled data in Figure 2B; raw data in Figure 2C), with the difference
large in magnitude (Table 2). Re-analyses of the ORCA-LLT learning
curves using untransformed data also yielded a significant interaction
betweenAPOE ε4 and time, albeitwith a smaller effect size, d (95%con-
fidence interval)= 1.18 (0.48, 1.84), P< .001.
4 DISCUSSION
Our study shows that in Aβ– CN older adults, the APOE ε4 allele is
associated with a reduced ability to learn, or put more broadly, as a
reduced ability to benefit from experience. One manifestation of this
is a reduction in the practice effect expected from 9 years of retesting
on neuropsychological tests that yield the AIBL episodic memory com-
posite (Figure 2A). However, despite the considerable length of follow-
up, number of reassessments using the same versions of the memory
tests, and sample size, the magnitude of the reduced practice effect in
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F IGURE 2 Effect of APOE ε4 on episodic memory performance over 108monthsmodeled using unadjusted estimates (A), andORCA-LLT
performance over 6 days, modeled using linear mixedmodel (B), and raw groupmeans (C). Shaded areas and error bars represent 95% confidence
intervals. Aβ, amyloid beta; APOE, apolipoprotein E; ORCA-LLT, Online Repeatable Cognitive Assessment-Language Learning Test
TABLE 2 Mean slopes (SD) and Cohen’s d representing groupmean slope differences from themixed-effects model on episodic memory
performance in the broader AIBL sample, and accuracy of performance on theORCA-LLT
AIBL CN full sample (outcome: EM
composite)
ORCACN subsample (outcome: ORCA-LLT
accuracy)
β (SE) P β (SE) P
APOE ε4 –0.195 (0.117) .096 –0.311 (0.184) .097
Age –0.291 (0.045) <.001 –0.028 (0.082) .734
Time 0.148 (0.013) <.001 0.752 (0.020) <.001
APOE ε4× Time –0.068 (0.031) .027 –0.147 (0.040) <.001
Mean (SD) N Mean (SD) N
Aβ- ε4 non-carrier 0.148 (0.215) 273 0.752 (0.118) 35
Aβ- ε4 carrier 0.079 (0.215) 60 0.604 (0.126) 13
Cohen’s d (95%CI) 0.32 (0.04, 0.60) 1.23 (0.53, 1.89)
Abbreviations: AIBL, Australian Imaging, Biomarkers and Lifestyle (AIBL) study; APOE, apolipoprotein E; CI, confidence interval; CN, cognitively normal;
EM, Episodic memory; ORCA-LLT, Online Repeatable Cognitive Assessment-Language Learning Test; SD, standard deviation; SE, standard error.
Notes: Bolded values are significant at P< .05; all β estimates reported have been standardized.
the Aβ–CN ε4 groupwas only small tomoderate (d= 0.3).More proac-
tively, in ε4 carriers, the reduced ability to benefit from experiencewas
evident from only 6 days of testing on the ORCA-LLT. In the ORCA
paradigm, the failure to benefit from experiencemanifested in the sub-
stantially lower ability of theAβ–CN ε4 carriers to learn a set of 50Chi-
nese character-English word pairs, with the magnitude of this reduc-
tion much larger (d = 1.2) than that observed for the episodic memory
composite (Figure 2B).
Reduced practice effects on episodic memory tests have been
observed previously in preclinical AD groups from AIBL and other
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prospective studies,8–10 although the magnitude of these reductions
(d = 0.4) have been only slightly larger than those observed between
the current sample of Aβ– ε4 carriers and non-carriers. Recent inves-
tigations into Aβ– individuals have identified subsets with faster Aβ
accumulation,7 particularly in ε4 carriers,6 although no study has
observed memory decline in either AD risk groups when individuals
who progressed to MCI/AD were excluded.7 The large deficit in learn-
ing observed inAβ– ε4 carriers on theORCA-LLT is qualitatively similar
to that reported previously, albeit with a slightly reduced magnitude,
in the comparison of older adults with preclinical AD to Aβ– controls
(ie, d > 2).12 While this learning deficit likely reflects the deleterious
effects of accumulating Aβ on the neurons or synapses necessary for
the acquisition of new information, the precise biological basis of this
interaction requires further exploration.
The learning paradigm used in the ORCA-LLT was based on experi-
mental psychologicalmodels;22,23 however, themodification to require
aspects of language learning makes the outcomes of this study directly
generalizable to the functional aspects of daily living of older adults
at risk of developing AD.15 The large learning deficit observed in
older adults who carried a strong genetic risk factor for AD, but
for whom Aβ levels had not reached current thresholds of abnor-
mality, suggest that the earliest AD-related cognitive dysfunction in
otherwise CN older adults will be evident when they are required
to acquire new and complex information, such as learning aspects
of a new language. Future studies will be required to determine
the extent to which acquisition of other novel and complex infor-
mation would be similarly impaired (eg, learning a new technical
procedure).
There are several limitations to consider when interpreting the
results of our study. First, only a small subset of Aβ– ε4 carriers com-
pleted the ORCA-LLT as the number of ε4 carriers who remained Aβ–
after 12 to 13 years of follow-up in AIBL was substantially reduced.
However, despite our small sample size, we observed a high rate of
completion (98%) on the ORCA-LLT. Additionally, our previous obser-
vation that short-term learning deficits in preclinical AD were very
large (d > 2),12 which provided reassurance that even with this rela-
tively small sample size, we would have sufficient power to observe
a qualitatively similar deficit in Aβ– ε4 carriers. When considered
together with the reduced practice effect observed over years, the
learning deficits observed over days provides an important founda-
tion for challenges of this approach in larger samples of older, or even
middle-aged, Aβ– ε4 carriers, which may help to further clarify the
nature and magnitude of this effect and elucidate its bases in mod-
els of AD pathogenesis. Second, individuals with substantial cardio-
vascular disease were excluded from enrollment into the AIBL study.
As such, while it is unlikely that the learning deficit observed here in
Aβ– ε4 carriers could be attributed to cardiovascular disease, it will be
important for future studies to determine the extent to which other
neuroinflammatory, cerebrovascular, or neurodegenerative processes
may be related to this learning deficit. Finally, while theORCA-LLTwas
designed to be a prospective measure of learning, we did not exam-
ine the extent to which performance on the ORCA-LLT changes over
longer periods of time (eg, 1–2 years). It will be important for future
studies to determine whether the nature and magnitude of learning
rates change over time.
These limitations notwithstanding, the consistent observation that
AD risk factors such as Aβ accumulation and APOE ε4 are associated
with substantial learning deficits, that can be detected over days, sup-
ports the hypothesis that cognitive dysfunction in early AD manifests
as a failure to benefit from experience. Furthermore, the presence of
this large learning deficit in Aβ– CN ε4 carriers shows, perhaps for the
first time, that AD-related clinical abnormalities can manifest strongly
in CN individuals even before they reach thresholds that currently
define preclinical AD.
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